Generic placeholder image

Current Nanomaterials

Author(s): Ladi Alik Kumar, Gurudutta Pattnaik, Bhabani Sankar Satapathy*, Dibyalochan Mohanty, P.A. Prasanth, Suddhasattya Dey and Jitendra Debata

DOI: 10.2174/0124054615274558231011164603

DownloadDownload PDF Flyer Cite As
Preparation and Optimization of Gemcitabine Loaded PLGA Nanoparticle Using Box-Behnken Design for Targeting to Brain: In Vitro Characterization, Cytotoxicity and Apoptosis Study

Page: [324 - 338] Pages: 15

  • * (Excluding Mailing and Handling)

Abstract

Background: Treatment of glioma with conventional approaches remains a far-reaching target to provide the desired outcome. This study aimed to develop and optimize Gemcitabine hydrochloride- loaded PLGA nanoparticles (GNPs) using the Box-Behnken design methodology. The independent variables chosen for this study included the quantity of Polymer (PLGA) (X1), Tween 80 (X2), and Sonication time (X3), whereas the dependent variables were Particle size (Y1) EE % (Y2) and PDI (Y3). The optimized biodegradable nanoparticles were investigated for their anticancer effectiveness in U87MG human glioblastoma cells in vitro.

Method: The formulation process involved two steps. Initially, emulsification was carried out by combining the organic polymer solution with the aqueous surfactant solution. Subsequently, in the second step, the organic solvent was evaporated, resulting in the precipitation of the polymer and the formation of nanoparticles. The quantity of PLGA, Tween 80, and PVA (at a constant concentration) was adjusted based on the experimental trial approach. Subsequently, the PLGA-based nanoparticles underwent characterization, wherein their particle size, encapsulation efficiency, polydispersity index (PDI), and cumulative release were assessed. The optimal formulation composition was determined as 200 mg of PLGA, 4 ml of Tween 80, and 2 mg of PVA. Further, the optimized GNPs were evaluated for their anti-cancer effectiveness on U87 MG cells by MTT and apoptosis assay.

Results: The results demonstrated that the optimized GNPs exhibited an encapsulation efficiency of 81.66 %, a particle size of 140.1 nm, and a PDI of 0.37. The morphology of the Opt-GNPs was observed to be spherical through transmission electron microscopy (TEM).

Conclusion: The Apoptosis study further confirmed the observations of MTT assay as the Opt- GNPs significantly enhanced the apoptosis in U-87 MG cells than the Standard marketed formulation.

Graphical Abstract

[1]
Mohanty D, Gilani SJ, Zafar A, et al. Formulation and optimization of alogliptin-loaded polymeric nanoparticles: In vitro to in vivo assessment. Molecules 2022; 27(14): 4470.
[http://dx.doi.org/10.3390/molecules27144470] [PMID: 35889343]
[2]
Satapathy BS, Kumar LA, Pattnaik G, Swapna S, Mohanty D. Targeting to brain tumor: Nanocarrier-based drug delivery platforms, opportunities, and challenges. J Pharm Bioallied Sci 2021; 13(2): 172-7.
[http://dx.doi.org/10.4103/jpbs.JPBS_239_20] [PMID: 34349476]
[3]
Satapathy BS, Kumar LA, Pattnaik G, Barik B. Lomustine incorporated lipid nanostructures demonstrated preferential anticancer properties in C6 glioma cell lines with enhanced pharmacokinetic profile in mice. Acta Chim Slov 2021; 68(4): 970-82.
[http://dx.doi.org/10.17344/acsi.2021.6977] [PMID: 34918770]
[4]
Satpathy BS, Barik B, Kumar LA, Biswal S. Potential of lipid based nanodrug carriers for targeted treatment of glioblastoma: Recent progress and challenges ahead In:. Glioblastoma. IntechOpen 2022.
[5]
Kumar LA, Satapathy BS, Pattnaik G, Barik B, Patro CS, Das S. Malignant brain tumor: Current progresses in diagnosis, treatment and future strategies. Ann Rom Soc Cell Biol 2021; 25(6): 16922-32.
[6]
Satapathy BS, Biswal SK, Maharana L, Pattnaik S. Bioactive Components of piper betel Could be Potential anticancer Agents: A short Review on Pre-clinical Inves-Tigations and Practical Challenges. Curr Trends Biotechnol Pharm 2023; 17(2): 918-29.
[7]
Satapathy BS, Pattnaik S, Biswal SK, et al. Recent advancements in phyto component based nanocarriers for improved treatment of brain disorders.In: Drug Repurposing intechopen. 2023.
[http://dx.doi.org/10.5772/intechopen.110585]
[8]
Mahapatra A, Saha S, Munda S, Bhabani SS, Meher S, Jangde HK. Bio-efficacy of herbicide mixtures on weed dynamics in direct wet-seeded rice. Indian J Weed Sci 2023; 55(1): 18-23.
[http://dx.doi.org/10.5958/0974-8164.2023.00003.5]
[9]
Panda J, Satapathy BS, Majumder S, Sarkar R, Mukherjee B, Tudu B. Engineered polymeric iron oxide nanoparticles as potential drug carrier for targeted delivery of docetaxel to breast cancer cells. J Magn Magn Mater 2019; 485: 165-73.
[http://dx.doi.org/10.1016/j.jmmm.2019.04.058]
[10]
Panda J, Satapathy BS, Mandal B, et al. Anticancer potential of docetaxel-loaded cobalt ferrite nanocarrier: An in vitro study on MCF-7 and MDA-MB-231 cell lines. J Microencapsul 2021; 38(1): 36-46.
[http://dx.doi.org/10.1080/02652048.2020.1842529] [PMID: 33206010]
[11]
Soni G, Kale K, Shetty S, Gupta MK, Yadav KS. Quality by design (QbD) approach in processing polymeric nanoparticles loading anticancer drugs by high pressure homogenizer. Heliyon 2020; 6(4): e03846.
[http://dx.doi.org/10.1016/j.heliyon.2020.e03846] [PMID: 32373744]
[12]
Wadhwa G, Krishna KV, Dubey SK, Taliyan R. Development and validation of RP-HPLC method for quantification of repaglinide in mPEG-PCL polymeric nanoparticles: QbD-driven optimization, force degradation study, and assessment of in vitro release mathematic modeling. Microchem J 2021; 168: 106491.
[http://dx.doi.org/10.1016/j.microc.2021.106491]
[13]
Ghose D, Patra CN, Ravi Kumar BVV, et al. QbD-based formulation optimization and characterization of polymeric nanoparticles of cinacalcet hydrochloride with improved biopharmaceutical attributes. Turk J Pharm Sci 2021; 18(4): 452-64.
[http://dx.doi.org/10.4274/tjps.galenos.2020.08522] [PMID: 34496552]
[14]
Canchi A, Khosa A, Singhvi G, Banerjee S, Dubey SK. Design and characterization of polymeric nanoparticles of pioglitazone hydrochloride and study the effect of formulation variables using QbD approach. Curr Nanomater 2018; 2(3): 162-8.
[http://dx.doi.org/10.2174/2405461503666180501115359]
[15]
Zeeshan M, Ali H, Ain QU, et al. A holistic QBD approach to design galactose conjugated PLGA polymer and nanoparticles to catch macrophages during intestinal inflammation. Mater Sci Eng C 2021; 126: 112183.
[http://dx.doi.org/10.1016/j.msec.2021.112183] [PMID: 34082983]
[16]
Adin SN, Gupta I, Aqil M, Mujeeb M. Application of QbD based approach in development and validation of RP‐HPLC method for simultaneous estimation of methotrexate and baicalin in dual‐drug‐loaded liposomes. Biomed Chromatogr 2023; 37(4): e5581.
[http://dx.doi.org/10.1002/bmc.5581] [PMID: 36609805]
[17]
de Oliveira TC, Oliveira ACJ, Patriota YBG, et al. Eco-friendly synthesis of phthalate angico gum towards nanoparticles engineering using Quality by Design (QbD) approach. Int J Biol Macromol 2021; 190: 801-9.
[http://dx.doi.org/10.1016/j.ijbiomac.2021.09.012] [PMID: 34508723]
[18]
Rizg WY, Naveen NR, Kurakula M, et al. QbD supported optimization of the alginate-chitosan nanoparticles of simvastatin in enhancing the anti-proliferative activity against tongue carcinoma. Gels 2022; 8(2): 103.
[http://dx.doi.org/10.3390/gels8020103] [PMID: 35200484]
[19]
Zagalo DM, Silva BMA, Silva C, Simões S, Sousa JJ. A quality by design (QbD) approach in pharmaceutical development of lipid-based nanosystems: A systematic review. J Drug Deliv Sci Technol 2022; 70: 103207.
[http://dx.doi.org/10.1016/j.jddst.2022.103207]
[20]
Marto J, Gouveia LF, Gonçalves LM, et al. A Quality by design (QbD) approach on starch-based nanocapsules: A promising platform for topical drug delivery. Colloids Surf B Biointerfaces 2016; 143: 177-85.
[http://dx.doi.org/10.1016/j.colsurfb.2016.03.039] [PMID: 27003468]
[21]
Sreeharsha N, Rajpoot K, Tekade M, et al. Development of metronidazole loaded chitosan nanoparticles using QbD approach—A novel and potential antibacterial formulation. Pharmaceutics 2020; 12(10): 920.
[http://dx.doi.org/10.3390/pharmaceutics12100920] [PMID: 32992903]
[22]
Jena GK, Patra CN, Panigrahi KC, Sruti J, Patra P, Parhi R. QbD enabled optimization of solvent shifting method for fabrication of PLGA-based nanoparticles for promising delivery of Capecitabine for antitumor activity. Drug Deliv Transl Res 2021; 1-9.
[PMID: 34505271]
[23]
Khuroo T, Khuroo A, Hussain A, et al. Qbd based and Box-Behnken design assisted Oral delivery of stable lactone (active) form of Topotecan as PLGA nanoformulation: Cytotoxicity, pharmacokinetic, in vitro, and ex vivo gut permeation studies. J Drug Deliv Sci Technol 2022; 77: 103850.
[http://dx.doi.org/10.1016/j.jddst.2022.103850]
[24]
Saha M, Saha DR, Ulhosna T, et al. QbD based development of resveratrol-loaded mucoadhesive lecithin/chitosan nanoparticles for prolonged ocular drug delivery. J Drug Deliv Sci Technol 2021; 63: 102480.
[http://dx.doi.org/10.1016/j.jddst.2021.102480]
[25]
Park J, Mattessich T, Jay SM, Agawu A, Saltzman WM, Fahmy TM. Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates. J Control Release 2011; 156(1): 109-15.
[http://dx.doi.org/10.1016/j.jconrel.2011.06.025] [PMID: 21723893]
[26]
Karra N, Nassar T, Ripin AN, Schwob O, Borlak J, Benita S. Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: efficacy and biofate in a lung cancer mouse model. Small 2013; 9(24): 4221-36.
[http://dx.doi.org/10.1002/smll.201301417] [PMID: 23873835]
[27]
Mohanty D, Alsaidan OA, Zafar A, et al. Development of atomoxetine-loaded NLC in situ gel for nose-to-brain delivery: Optimization, in vitro, and preclinical evaluation. Pharmaceutics 2023; 15(7): 1985.
[http://dx.doi.org/10.3390/pharmaceutics15071985] [PMID: 37514171]
[28]
Satapathy S, Patro CS. Solid lipid nanoparticles for efficient oral delivery of tyrosine kinase inhibitors: A nano targeted cancer drug delivery. Adv Pharm Bull 2022; 12(2): 298-308.
[PMID: 35620346]
[29]
Cunha S, Costa CP, Moreira JN, Sousa Lobo JM, Silva AC. Using the quality by design (QbD) approach to optimize formulations of lipid nanoparticles and nanoemulsions: A review. Nanomedicine 2020; 28: 102206.
[http://dx.doi.org/10.1016/j.nano.2020.102206] [PMID: 32334097]
[30]
Raina H, Kaur S, Jindal AB. Development of efavirenz loaded solid lipid nanoparticles: Risk assessment, quality-by-design (QbD) based optimisation and physicochemical characterisation. J Drug Deliv Sci Technol 2017; 39: 180-91.
[http://dx.doi.org/10.1016/j.jddst.2017.02.013]
[31]
Arora D, Bhatt S, Kumar M, et al. QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer’s therapeutics. Front Aging Neurosci 2022; 14: 960246.
[http://dx.doi.org/10.3389/fnagi.2022.960246] [PMID: 36034142]
[32]
Waheed A, Zameer S, Sultana N, et al. Engineering of QbD driven and ultrasonically shaped lyotropic liquid crystalline nanoparticles for Apigenin in the management of skin cancer. Eur J Pharm Biopharm 2022; 180: 269-80.
[http://dx.doi.org/10.1016/j.ejpb.2022.10.015] [PMID: 36272654]
[33]
Jhawat V, Gulia M, Gupta S, Maddiboyina B, Dutt R. Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy. J Control Release 2020; 327: 500-11.
[http://dx.doi.org/10.1016/j.jconrel.2020.08.039] [PMID: 32858073]
[34]
Gurumukhi VC, Bari SB. Quality by design (QbD)–based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies. Drug Deliv Transl Res 2022; 12(5): 1230-52.
[http://dx.doi.org/10.1007/s13346-021-01014-4] [PMID: 34110597]
[35]
Sabir F, Katona G, Ismail R, Sipos B, Ambrus R, Csóka I. Development and characterization of n-propyl gallate encapsulated solid lipid nanoparticles-loaded hydrogel for intranasal delivery. Pharmaceuticals 2021; 14(7): 696.
[http://dx.doi.org/10.3390/ph14070696] [PMID: 34358121]
[36]
Correia AC, Monteiro AR, Silva R, Moreira JN, Sousa Lobo JM, Silva AC. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood–brain barrier (BBB) to manage neurological disorders. Adv Drug Deliv Rev 2022; 189: 114485.
[http://dx.doi.org/10.1016/j.addr.2022.114485] [PMID: 35970274]
[37]
Singh S, Maurya P, Rani S, et al. Development of doxorubicin hydrochloride–loaded whey protein nanoparticles and its surface modification with N-acetyl cysteine for triple-negative breast cancer. Drug Deliv Transl Res 2022; 12(12): 3047-62.
[http://dx.doi.org/10.1007/s13346-022-01169-8] [PMID: 35499714]
[38]
Wibowo D, Jorritsma SHT, Gonzaga ZJ, Evert B, Chen S, Rehm BHA. Polymeric nanoparticle vaccines to combat emerging and pandemic threats. Biomaterials 2021; 268: 120597.
[http://dx.doi.org/10.1016/j.biomaterials.2020.120597] [PMID: 33360074]
[39]
Mohanty D, Zafar A, Jafar M, et al. Development, in-vitro characterization and preclinical evaluation of esomeprazole-encapsulated proniosomal formulation for the enhancement of anti-ulcer activity. Molecules 2022; 27(9): 2748.
[http://dx.doi.org/10.3390/molecules27092748] [PMID: 35566099]
[40]
Komati S, Swain S, Rao MEB, Jena BR, Unnam S, Dasi V. QbD-based design and characterization of mucoadhesive microspheres of quetiapine fumarate with improved oral bioavailability and brain biodistribution potential. Bull Fac Pharm Cairo Univ 2018; 56(2): 129-45.
[http://dx.doi.org/10.1016/j.bfopcu.2018.09.002]
[41]
Swain S, Parhi R, Jena BR, Babu SM. Quality by design: Concept to applications. Curr Drug Discov Technol 2019; 16(3): 240-50.
[http://dx.doi.org/10.2174/1570163815666180308142016] [PMID: 29521238]
[42]
Komati S, Swain S, Rao MEB, Jena BR, Dasi V. Mucoadhesive multiparticulate drug delivery systems: An extensive review of patents. Adv Pharm Bull 2019; 9(4): 521-38.
[http://dx.doi.org/10.15171/apb.2019.062] [PMID: 31857957]
[43]
Swain S, Jena BR, Madugula D, Beg S. Application of quality by design paradigms for development of solid dosage forms.In: Pharmaceutical quality by design. Academic Press 2019; pp. 109-30.
[http://dx.doi.org/10.1016/B978-0-12-815799-2.00007-1]
[44]
Jena BR, Panda SP, Umasankar K, et al. Applications of QbD-based software’s in analytical research and development. Curr Pharm Anal 2021; 17(4): 461-73.
[http://dx.doi.org/10.2174/1573412916666200108155853]
[45]
Jena BR, Panda SP, Kulandaivelu U, et al. AQbD driven development of an RP-HPLC method for the quantitation of abiraterone acetate for its pharmaceutical formulations in the presence of degradants. Turk J Pharm Sci 2021; 18(6): 718-29.
[http://dx.doi.org/10.4274/tjps.galenos.2021.74150] [PMID: 34978401]
[46]
Jena BR, Panda SP, Umasankar K, et al. Analytical QbD based systematic development of a novel RP-UHPLC method for quantification of albuterol sulphate in its metered dose inhaler formulations. J Res Pharm 2021; 25(5): 689-701.
[47]
Jena BR, Panda SP, Kulandaivelu U, et al. A QbD based study in development, optimization and forced degradation behaviour of Epinastine Hydrochloride in Metered dose inhaler by RP-HPLC. Int J Pharm Res 2021; 13(1): 735-47.
[48]
Mishra H, Behera A, Sankar Kar S, Pattnaik G, Kanhar S, Dash S. Analytical strategies for the detection and quantification of nano-formulated antibiotics: Updates and perspectives. J Pharm Res Int 2021; 384-95.
[http://dx.doi.org/10.9734/jpri/2021/v33i59A34282]
[49]
Sumera AF, Anwer F, Waseem M, et al. Molecular docking and molecular dynamics studies reveal secretory proteins as novel targets of temozolomide in glioblastoma multiforme. Molecules 2022; 27(21): 7198.
[http://dx.doi.org/10.3390/molecules27217198] [PMID: 36364024]
[50]
Poustforoosh A, Faramarz S, Nematollahi MH, et al. 3D‐QSAR, molecular docking, molecular dynamics, and ADME/T analysis of marketed and newly designed flavonoids as inhibitors of Bcl‐2 family proteins for targeting U‐87 glioblastoma. J Cell Biochem 2022; 123(2): 390-405.
[http://dx.doi.org/10.1002/jcb.30178] [PMID: 34791695]
[51]
Bhattacharjee R, Devi A, Mishra S. Molecular docking and molecular dynamics studies reveal structural basis of inhibition and selectivity of inhibitors EGCG and OSU-03012 toward glucose regulated protein-78 (GRP78) overexpressed in glioblastoma. J Mol Model 2015; 21(10): 272.
[http://dx.doi.org/10.1007/s00894-015-2801-3] [PMID: 26419972]
[52]
Fujikawa A, Nagahira A, Sugawara H, et al. Small-molecule inhibition of PTPRZ reduces tumor growth in a rat model of glioblastoma. Sci Rep 2016; 6(1): 20473.
[http://dx.doi.org/10.1038/srep20473] [PMID: 26857455]
[53]
Roy PK, Majumder R, Mandal M. In-silico identification of novel DDI2 inhibitor in glioblastoma via repurposing FDA approved drugs using molecular docking and MD simulation study. J Biomol Struct Dyn 2023; 1-12.
[http://dx.doi.org/10.1080/07391102.2023.2204371] [PMID: 37139547]
[54]
Govindaraj M, Suresh M, Palaniyandi T, et al. Bio-fabrication of gold nanoparticles from brown seaweeds for anticancer activity against glioblastoma through invitro and molecular docking approaches. J Mol Struct 2023; 1281: 135178.
[http://dx.doi.org/10.1016/j.molstruc.2023.135178]
[55]
Li T, Xiao Y, Wang Z, Xiao H, Liu H. The mechanism study of common flavonoids on antiglioma based on network pharmacology and molecular docking. Evid Based Complement Alternat Med 2022; 2022: 1-15.
[http://dx.doi.org/10.1155/2022/2198722] [PMID: 35140796]
[56]
Westphal M, Maire CL, Lamszus K. EGFR as a target for glioblastoma treatment: An unfulfilled promise. CNS Drugs 2017; 31(9): 723-35.
[http://dx.doi.org/10.1007/s40263-017-0456-6] [PMID: 28791656]
[57]
Miranda A, Cova T, Sousa J, Vitorino C, Pais A. Computational modeling in glioblastoma: From the prediction of blood–brain barrier permeability to the simulation of tumor behavior. Future Med Chem 2018; 10(1): 121-31.
[http://dx.doi.org/10.4155/fmc-2017-0128] [PMID: 29235374]
[58]
Dong Q, Wang D, Li L, et al. Biochanin A sensitizes glioblastoma to temozolomide by inhibiting autophagy. Mol Neurobiol 2022; 59(2): 1262-72.
[http://dx.doi.org/10.1007/s12035-021-02674-6] [PMID: 34981417]
[59]
Huang J, Zhou Y, Zhong X, Su F, Xu L. Effects of vitexin, a natural flavonoid glycoside, on the proliferation, invasion, and apoptosis of human U251 glioblastoma cells. Oxid Med Cell Longev 2022; 2022: 1-13.
[http://dx.doi.org/10.1155/2022/3129155] [PMID: 35281458]
[60]
Wu N, Liu J, Zhao X, et al. Cardamonin induces apoptosis by suppressing STAT3 signaling pathway in glioblastoma stem cells. Tumour Biol 2015; 36(12): 9667-76.
[http://dx.doi.org/10.1007/s13277-015-3673-y] [PMID: 26150336]
[61]
Sun J, Wang H, Cheng G, et al. Revealing the action mechanisms of scutellarin against glioblastoma based on network pharmacology and experimental validation. Food Sci Technol 2022; 42: e106121.
[http://dx.doi.org/10.1590/fst.106121]
[62]
Takahashi H, Hase H, Yoshida T, et al. Discovery of two novel ALKBH5 selective inhibitors that exhibit uncompetitive or competitive type and suppress the growth activity of glioblastoma multiforme. Chem Biol Drug Des 2022; 100(1): 1-12.
[http://dx.doi.org/10.1111/cbdd.14051] [PMID: 35384315]
[63]
Gholivand K, Faraghi M, Fallah N, et al. Therapeutic potential of phospho-thiadiazole derivatives as anti-glioblastoma agents: synthesis, biological assessment and computational study. Bioorg Chem 2022; 129: 106123.
[http://dx.doi.org/10.1016/j.bioorg.2022.106123] [PMID: 36108588]
[64]
Netto JB, Melo ESA, Oliveira AGS, et al. Matteucinol combined with temozolomide inhibits glioblastoma proliferation, invasion, and progression: an in vitro, in silico, and in vivo study. Braz J Med Biol Res 2022; 55: e12076.
[http://dx.doi.org/10.1590/1414-431x2022e12076] [PMID: 36000612]
[65]
Mokgautsi N, Wen YT, Lawal B, et al. An integrated bioinformatics study of a novel niclosamide derivative, nsc765689, a potential gsk3β/β-catenin/stat3/cd44 suppressor with anti-glioblastoma properties. Int J Mol Sci 2021; 22(5): 2464.
[http://dx.doi.org/10.3390/ijms22052464] [PMID: 33671112]
[66]
Yang X, Lu D, Sun Y, et al. Network pharmacology and experimental verification reveal the mechanism of safranal against glioblastoma (GBM). Front Oncol 2023; 13: 1255164.
[http://dx.doi.org/10.3389/fonc.2023.1255164] [PMID: 37736545]
[67]
Yang W, Xiang Y, Liao MJ, et al. Presenilin1 inhibits glioblastoma cell invasiveness via promoting Sortilin cleavage. Cell Commun Signal 2021; 19(1): 112.
[http://dx.doi.org/10.1186/s12964-021-00780-5] [PMID: 34781973]
[68]
Ferrari IV, De Gregorio A, Fuggetta MP, Ravagnan G. Molecular docking studies against glioblastoma proteins. Int J Sci Res Biol Sci 2023; 10(2)
[69]
Huff S, Tiwari SK, Gonzalez GM, Wang Y, Rana TM. m6A-RNA demethylase FTO inhibitors impair self-renewal in glioblastoma stem cells. ACS Chem Biol 2021; 16(2): 324-33.
[http://dx.doi.org/10.1021/acschembio.0c00841] [PMID: 33412003]
[70]
Viswanathan A, Musa A, Murugesan A, et al. Battling glioblastoma: A novel tyrosine kinase inhibitor with multi-dimensional anti-tumor effect. Cells 2019; 8(12): 1624.
[http://dx.doi.org/10.3390/cells8121624] [PMID: 31842391]
[71]
Kumari S, Kumar P. Design and computational analysis of an mmp9 inhibitor in hypoxia-induced glioblastoma multiforme. ACS Omega 2023; 8(11): 10565-90.
[http://dx.doi.org/10.1021/acsomega.3c00441] [PMID: 36969457]
[72]
Affram KO, Smith T, Ofori E, et al. Cytotoxic effects of gemcitabine-loaded solid lipid nanoparticles in pancreatic cancer cells. J Drug Deliv Sci Technol 2020; 55: 101374.
[http://dx.doi.org/10.1016/j.jddst.2019.101374] [PMID: 31903101]